Issue 030.

Get E&O weekly. | Subscribe | Digital health research from Brian Dolan.

Welcome to E&O.

Last week's newsletter had a 62 percent open rate. Here's what's happening this week:

• My backyard now features both a seven-foot-tall snowman and his companion snowdog, following the Greater Boston area's first snowstorm of the season.
• Foley's telemedicine report focused on commercial payer laws throughout the US is well worth a read.
• Nothing new but... in his first interview since assuming the post in July, when asked what changes he's made so far, Sandoz's top exec Richard Saynor told a German newspaper: "We decided to quit the business with so-called digital therapeutics (for example, apps that help addicts, ed.). While this is a fascinating area, it does not really suit the commercialization of generics." (translated from German) via FiercePharma
• Swedish specialty pharmaco Orexo has